Results 181 to 190 of about 119,169 (307)

Evaluating CTLA-4 Antibody-Antigen Binding as a Model for Targeted Immunosuppressant Delivery in Hashimoto's Thyroiditis. [PDF]

MicroPubl Biol
Tiruvellore V, Koegle M.
europepmc   +1 more source

Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis

Rheumatology &Autoimmunity, EarlyView.
Patient‐reported outcomes (PROs) were compared among rheumatoid arthritis patients who maintained low disease activity or remission for at least 6 months based on the disease‐modifying antirheumatic drug (DMARD)administered. Even with comparable disease activity, methotrexate (MTX) group, biological/targeted synthetic DMARDs (b/tsDMARDs), particularly ...
Masafumi Sugiyama, Saki Okuda‐Tsuchimoto, Takashi tsuchimoto, Koji Kinoshita, Itaru Matsumura   +4 more
wiley   +1 more source

PD-1,CTLA-4

Okayama Igakkai Zasshi (Journal of Okayama Medical Association), 2015
openaire   +2 more sources

Identification of genetically predicted protein biomarkers and drug targets for prostate cancer via Mendelian randomization

VIEW, EarlyView.
Prostate cancer, a leading cause of cancer in men globally, urgently requires improved diagnostic and treatment strategies. This study analyzed large genetic datasets and identified five key proteins (THBD, DST, IFI27L2, OSBPL10, PPP1R14A) that either increase or decrease cancer risk, while also exploring their roles in immune response and potential ...
Maoping Cai, Tianming Peng, Zhiyue Xie, Chuqian Zhen, Chen Yao, Nan Peng, Qianyi Li, Yuzhong Yu, Jiming Bao, Xian‐Lu Song, Mingkun Chen, Shan‐Chao Zhao   +11 more
wiley   +1 more source

Host immunogenetics and EBV detection in cancer: the CTLA-4 rs231775 signal in a multi-cancer case-control cohort. [PDF]

Infect Agent Cancer
Abed NK, Bayrami A, Zahri S.
europepmc   +1 more source

Potential targets for renal cell carcinoma therapy: Mechanistic research and prospects of CAFs in renal cell carcinoma

VIEW, EarlyView.
Cancer‐associated fibroblasts exert intricate mechanisms in the progression and metastasis of renal cell carcinoma. Existing studies have validated the relevant mechanisms of three signaling pathways, which hold promising potential as novel therapeutic targets.
Ruiqiang Sun, Jiankun Zhang, Meixi Liu, Xiyue Dong, Yuanshan Cui   +4 more
wiley   +1 more source

Advances in PD-1 and CTLA-4 dual-target immunotherapy for ovarian cancer. [PDF]

Front Immunol
Li DM, Pei KG, Yu XZ, Qie MR, Zhong L, Song L.   +5 more
europepmc   +1 more source

Enhancement of immune checkpoint inhibitor efficacy by DHX58+ SELL+ T cells in advanced gastric cancer

VIEW, EarlyView.
We created a coculture system using patient‐derived organoids (PDOs) and tumor‐infiltrating lymphocytes (TILs) that mimics important interactions between PDOs and TILs in the presence of various ICIs. Our findings reveal that CD62L+ T cells, activated by CD44+ cancer stem cells (CSCs), facilitate tumor regression in samples sensitive to ICIs, which is ...
Jie Chen, Youdong Liu, Hongda Pan, Tianyi Cai, Mingde Zang, Xiaowen Liu, Ziwen Long, Xin Fan, Jun Lu, Fenglin Liu   +9 more
wiley   +1 more source

Cadonilimab (mono anti-PD-1/CTLA-4 therapy) in advanced esophageal squamous cell carcinoma. [PDF]

J Immunother Cancer
Wang BC.
europepmc   +1 more source

Vulval Lichen Sclerosus Associated With Immune Checkpoint Inhibitor Therapy: A Case Series of 11 Patients

Australasian Journal of Dermatology, EarlyView.
ABSTRACT There have only been a limited number of case reports that have described vulval lichen sclerosus in patients receiving immune checkpoint inhibitor (ICI) therapy. We describe 11 cases of vulval lichen sclerosus in patients with melanoma treated with ICIs, and in nine of these cases, the lichen sclerosus symptoms began after ICI commencement ...
Sophie Walter, Francesca Watts, Raquel Ruiz Araujo, Thevaki Wain, Amanda Glanz, Diona Damian, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long, Linda K. Martin   +9 more
wiley   +1 more source